drugset / Trial / NCT07330999

Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults

NCT07330999 ↗

Recruiting 120 enrolled Poznan University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare three versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older who are undergoing hip surgery. The PENG block is a regional anesthesia technique used to reduce pain around the hip joint and may improve early recovery after surgery. All patients in the study will receive the PENG block using 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of three groups: Group 1: PENG block using ropivacaine only (no additional medications). Group 2: PENG block using ropivacaine with 4 mg of dexamethasone injected near the nerves. Group 3: PENG block using ropivacaine with 25 micrograms of dexmedetomidine injected near the nerves. Dexamethasone and dexmedetomidine are medications that may increase the duration and quality of regional anesthesia. It is not known whether adding one of these medications provides longer-lasting or better pain relief compared to using ropivacaine alone. The main purpose of this study is to determine whether the addition of dexamethasone or dexmedetomidine improves the effectiveness of the PENG block in relieving pain after hip surgery. The study will evaluate pain levels, opioid consumption, time to first rescue pain medication, need for additional analgesia, and recovery outcomes. Safety, side effects, and any block-related complications will also be monitored. The investigators hypothesize that adding either perineural dexamethasone or dexmedetomidine will result in longer and more effective pain relief compared with the standard PENG block without an adjuvant. This research may help identify the most effective form of the PENG block for older adults undergoing hip surgery and contribute to improved pain management, reduced opioid use, and better postoperative recovery.

Timeline

Start
2026-02-13
Primary completion
2027-01-01
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 4 mg Other
Comparator Dexmedetomidine Other / unclassified 25 ug Other
Comparator Ropivacaine Other / unclassified 20 ml Other

Indications